Please assess the completion status of the following clinical trial:

Trial Title: A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who were fully informed of and understand the objectives, procedures, and possible benefits and risks of the study and who provided written voluntary consent to participate in the study.~* Outpatients aged 18 through 74 years at the time of consent~* Patients meets DSM-IV-TR criteria for bipolar I disorder, most recent episode depressed (≥ 4 weeks and less than 12 months) without psychotic features.~Exclusion Criteria:~* Patients with imminent risk of suicide or injury to self, others, or property.~* Patients who had been hospitalized because of a manic or mixed episode within 60 days prior to screening.~* Patients who are otherwise considered ineligible for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): once daily orally
- SM-13496 20 - 60 mg/day (Type: EXPERIMENTAL): once daily orally
- SM-13496 80 - 120 mg/day (Type: EXPERIMENTAL): once daily orally

Based on this trial design, predict the completion outcome and termination type (if applicable).